Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTSO Cytosorbents	$1.03 +4.0%	$1.03	$0.71 ▼ $1.61	$61.98M	1.19	145,371 shs	22,379 shs
MDAI Spectral AI	$2.51 -6.0%	$2.06	$0.82 ▼ $3.25	$67.60M	0.9	899,740 shs	789,791 shs
PSTV Plus Therapeutics	$0.37 -3.0%	$0.34	$0.16 ▼ $2.31	$19.53M	0.69	10.69 million shs	7.24 million shs
ZYXI Zynex	$2.31 -1.7%	$2.33	$1.66 ▼ $10.47	$71.06M	0.83	174,382 shs	70,109 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTSO Cytosorbents	+4.04%	-2.83%	-11.21%	0.00%	-6.36%
MDAI Spectral AI	-5.99%	-12.24%	+19.52%	+102.42%	+31.41%
PSTV Plus Therapeutics	-3.00%	+3.28%	+83.46%	-43.59%	-79.30%
ZYXI Zynex	-1.70%	+3.12%	-4.15%	+5.96%	-77.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTSO Cytosorbents	1.7572 of 5 stars	3.5	1.0	2.9	0.0	0.6
MDAI Spectral AI	3.5615 of 5 stars	3.7	5.0	2.7	3.3	0.0
PSTV Plus Therapeutics	1.7106 of 5 stars	3.3	2.0	2.5	0.0	0.6
ZYXI Zynex	2.0226 of 5 stars	3.2	0.0	1.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTSO Cytosorbents	3.00	Buy	$5.50	433.98% Upside
MDAI Spectral AI	3.33	Buy	$4.75	89.24% Upside
PSTV Plus Therapeutics	2.50	Moderate Buy	$10.83	2,816.11% Upside
ZYXI Zynex	2.33	Hold	$5.50	138.10% Upside

Current Analyst Ratings Breakdown

Latest PSTV, MDAI, CTSO, and ZYXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ZYXI Zynex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $3.00
6/30/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/27/2025	PSTV Plus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.50 ➝ $3.00
6/25/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	PSTV Plus Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$9.00
6/5/2025	PSTV Plus Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $20.50
5/15/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	CTSO Cytosorbents	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.00 ➝ $1.00
5/5/2025	PSTV Plus Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/5/2025	PSTV Plus Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/2/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTSO Cytosorbents	$35.60M	1.81	N/A	N/A	$0.20 per share	5.15
MDAI Spectral AI	$29.58M	2.15	N/A	N/A	($0.32) per share	-7.84
PSTV Plus Therapeutics	$5.82M	3.26	N/A	N/A	($1.52) per share	-0.24
ZYXI Zynex	$192.35M	0.36	$0.24 per share	9.62	$1.12 per share	2.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTSO Cytosorbents	-$20.72M	-$0.28	N/A	N/A	N/A	-41.77%	-105.04%	-29.18%	8/12/2025 (Estimated)
MDAI Spectral AI	-$15.31M	-$0.54	N/A	N/A	N/A	-30.75%	N/A	-11.37%	N/A
PSTV Plus Therapeutics	-$12.98M	-$2.94	N/A	N/A	N/A	-520.90%	N/A	-202.73%	8/13/2025 (Estimated)
ZYXI Zynex	$2.99M	-$0.24	N/A	4.91	N/A	-4.30%	-23.70%	-6.23%	7/23/2025 (Estimated)

Latest PSTV, MDAI, CTSO, and ZYXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PSTV Plus Therapeutics	-$0.12	N/A	N/A	N/A	$1.08 million	N/A
8/12/2025	Q2 2025	CTSO Cytosorbents	-$0.07	N/A	N/A	N/A	$9.79 million	N/A
7/23/2025	Q2 2025	ZYXI Zynex	-$0.20	N/A	N/A	N/A	$27.38 million	N/A
5/30/2025	Q1 2025	PSTV Plus Therapeutics	-$0.17	-$0.56	-$0.39	-$1.19	$1.11 million	$1.06 million
5/14/2025	Q1 2025	CTSO Cytosorbents	-$0.08	-$0.06	+$0.02	-$0.02	$9.01 million	$8.73 million
4/28/2025	Q1 2025	ZYXI Zynex	-$0.24	-$0.33	-$0.09	-$0.33	$30.83 million	$26.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTSO Cytosorbents	N/A	N/A	N/A	N/A	N/A
MDAI Spectral AI	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTSO Cytosorbents	0.98	2.61	2.30
MDAI Spectral AI	N/A	1.41	1.37
PSTV Plus Therapeutics	N/A	1.03	1.03
ZYXI Zynex	2.87	3.46	2.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTSO Cytosorbents	32.87%
MDAI Spectral AI	67.08%
PSTV Plus Therapeutics	3.28%
ZYXI Zynex	29.68%

Insider Ownership

Company	Insider Ownership
CTSO Cytosorbents	7.30%
MDAI Spectral AI	30.70%
PSTV Plus Therapeutics	3.76%
ZYXI Zynex	49.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTSO Cytosorbents	220	62.61 million	58.04 million	Optionable
MDAI Spectral AI	83	25.32 million	17.55 million	Not Optionable
PSTV Plus Therapeutics	20	51.00 million	49.08 million	Not Optionable
ZYXI Zynex	770	30.24 million	15.34 million	Optionable

PSTV, MDAI, CTSO, and ZYXI Headlines

Recent News About These Companies

Zynex (NASDAQ:ZYXI) Price Target Lowered to $3.00 at Royal Bank Of Canada

July 17 at 2:37 AM | americanbankingnews.com

Zynex (ZYXI) to Release Quarterly Earnings on Wednesday

July 16 at 3:50 AM | marketbeat.com

Royal Bank Of Canada Issues Pessimistic Forecast for Zynex (NASDAQ:ZYXI) Stock Price

July 15, 2025 | marketbeat.com

Zynex: New CEO Steven Dyson shares his vision â€“ ICYMI

July 12, 2025 | proactiveinvestors.com

Zynex: New CEO Steven Dyson shares his vision – ICYMI

July 12, 2025 | proactiveinvestors.com

Zynex Shareholder Sues Board, Execs Over Insurer’s Payment Pause

July 11, 2025 | news.bloomberglaw.comN

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 10, 2025 | globenewswire.com

Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMI

July 5, 2025 | proactiveinvestors.com

Zynex says Tricare payment suspension to remain in place

July 3, 2025 | msn.com

Zynex stock falls after Tricare extends payment suspension

July 2, 2025 | uk.investing.com

Tricare Temporary Payment Suspension Update

July 2, 2025 | prnewswire.com

Zynex appoints Steven Dyson as new CEO

June 30, 2025 | msn.com

Zynex's (ZYXI) Buy Rating Reaffirmed at HC Wainwright

June 30, 2025 | marketbeat.com

Zynex taps Steve Dyson as chief executive officer

June 30, 2025 | proactiveinvestors.com

Zynex Announces Steven Dyson as New CEO

June 30, 2025 | prnewswire.com

Zynex awarded UK patent for non-invasive sepsis monitoring technology

June 25, 2025 | proactiveinvestors.com

Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis

June 25, 2025 | prnewswire.com

Zynex Announces Workforce Reduction

June 24, 2025 | marketwatch.com

Here’s Why Zynex (ZYXI) Fell in Q1

May 23, 2025 | msn.com

ZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens Berman

May 21, 2025 | morningstar.comM

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex

May 21, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV, MDAI, CTSO, and ZYXI Company Descriptions

Cytosorbents NASDAQ:CTSO

$1.03 +0.04 (+4.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.02 -0.01 (-0.49%)

As of 07/18/2025 04:08 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Spectral AI NASDAQ:MDAI

$2.51 -0.16 (-5.99%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.51 +0.00 (+0.04%)

As of 07/18/2025 07:43 PM Eastern

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

Plus Therapeutics NASDAQ:PSTV

$0.37 -0.01 (-3.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.36 -0.01 (-3.63%)

As of 07/18/2025 07:59 PM Eastern

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Zynex NASDAQ:ZYXI

$2.31 -0.04 (-1.70%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.01 (+0.43%)

As of 07/18/2025 04:04 PM Eastern

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time